Phase I clinical trial with ametantrone (NSC-287513).
D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000031:analogs & derivatives*; D009369:Neoplasms / Q000188:drug therapy*; D012880:Skin Pigmentation / Q000187:drug effects
D000880:Anthraquinones; D000970:Antineoplastic Agents; D008942:Mitoxantrone; C020182:ametantrone